SecBot SecBot

NVO

NOVO NORDISK A S
NYSE· Pharmaceutical Preparations· CIK 0000353278 Biotech & Drug Discovery
$41.60 −0.03 (−0.07%)
Nov 16 4:00 PM ET · prev $41.63
Market cap
$180.0B
Large cap
Consensus
Hold
28% Buy or better · 36 analysts
Median target
🔒 Subscribers only
1 year
−14.2%
from $48.46 · Nov 17
30 days
+8.3%
from $38.42
52-week range
$35.29–63.98
−35% from high · low Mar 30
Avg volume 20D
11.86M
shares / day
Short interest
38.29M
≈0.9% of shares · +2.3%
Days to cover
4.0
at average volume
New fund stakes
4
Q3 2026 13F · 6 exits
Reddit crowd
55°
Neutral · 6 mentions this week
Filing reports
43
analyzed by SecBot
SecBot read MIXED 22 reports · 90 days
Balance 0 bearish · 2 bullish · 20 neutral oldest → newest, height = score
Avg score ·High conf. 19/22

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InstitutionsMIXED

    Q3 2026: 48 added (4 new), 34 trimmed or exited. Largest new: Imc-Chicago $16.6M, Fiera Capital $14.8M.

  • AnalystsMIXED

    10 of 36 rate it Buy or better.

  • Short sellersSTEADY

    Short interest +2.3% to 38.29M shares. 4.0 days to cover, ≈0.9% of shares.

  • TrendUPTREND

    4% above its 50-day average.

  • SocialQUIET

    Crowd 55° (neutral) this week from 6 mentions: 1 bullish, 0 bearish. No setup is alerting.

Who's buying

13F· Q3 2026
4
new positions
6
exits
$31.4M
in new stakes · top 2 shown
FundMoveSharesValue
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPDOUBLED17,093,966$648.0M
RENAISSANCE TECHNOLOGIES LLCADD4,676,221$177.3M
BARCLAYS PLCADD3,428,026$130.0M
NATIXISDOUBLED2,393,807$90.7M
MARSHALL WACE, LLPADD2,161,795$82.0M
AMERICAN CENTURY COMPANIES INCADD1,837,188$69.6M
VAN ECK ASSOCIATES CORPADD1,525,067$57.8M
WCM INVESTMENT MANAGEMENT, LLCADD1,486,489$56.9M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

36 analysts
Hold 28% rate it Buy or better
Strong Buy4Buy6Hold20Sell5Strong Sell1

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Oct 12, 2026BMO Capital
MAINTAIN
MAINTAINMarket Perform
Sep 11, 2026Morgan Stanley
DOWNGRADE
DOWNGRADEUnderweight
Congressional trades
NVO trades disclosed by members of Congress, with disclosure delay.
1 members · 1 buys / 0 sells
DateMemberType AmountDisclosed
Aug 26, 2026 C. FranklinRHouse Novo Nordisk A/S BUY $1K–$15K Sep 17, 2026 +22d

Washington

Corporate Lobbying

107 lobbying filings and 9 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only
Reddit Mentions per day, 14 days
Crowd this week 55° Neutral 1 bullish · 0 bearish
Mentions, 7 days 6 0 in posts · 6 in comments
Recent posts
Recent comments
All social signals and their track records

Short side

FINRA· Oct 30, 2026
38,286,865
shares short
+2.3%
vs prior settlement
4.0
days to cover
≈0.9%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 13, 2026 Drug approval
EMA: Human medicines European public assessment report (EPAR): Donrafylix, insulin aspart, Status: Opinion
Human medicines European public assessment report (EPAR): Donrafylix, insulin aspart, Status: Opinio
Nov 13, 2026 SEC
A federal magistrate judge recommended granting summary judgment on liability to Novo Nordisk against MD Exam LLC for…
COURT-RULING · Impact 3/10
Nov 13, 2026 SEC
The court entered a stipulated protective order in Novo Nordisk's patent litigation against Mochi Health Corp…
COURT-RULING · Impact 1/10
Nov 13, 2026 Event
Novo Nordisk A/S et al v. Mochi Health Corp. et al
Court ruling (cand). Docket: 5:25-cv-06563
Oct 23, 2026 Event
AWIQLI FLEXTOUCH
Supplemental Approval · Efficacy · INJECTION
Sep 30, 2026 Inst.
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP · DOUBLED
17,093,966 shares ($648.0M)
Sep 30, 2026 Inst.
RENAISSANCE TECHNOLOGIES LLC · ADD
4,676,221 shares ($177.3M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
21 drugs tracked · Drug pipeline →
Recent
Nov 16, 2026
Clinical Trial
🔒 Fresh data, subscribers only
Nov 13, 2026
Drug approval
EMA: Human medicines European public assessment report (EPAR): Donrafylix, insulin aspart, Status: Opinion
Human medicines European public assessment report (EPAR): Donrafylix, insulin aspart, Status: Opinion
Nov 13, 2026
Drug approval
EMA: Human medicines European public assessment report (EPAR): Garzulys, insulin aspart, Status: Opinion
Human medicines European public assessment report (EPAR): Garzulys, insulin aspart, Status: Opinion
Nov 13, 2026
Enforcement
Novo Nordisk A/S et al v. Mochi Health Corp. et al
Court ruling (cand). Docket: 5:25-cv-06563
Nov 13, 2026
Enforcement
Novo Nordisk A/S et al v. MD Exam LLC
Court ruling (flsd). Docket: 1:24-cv-22064

SecBot reports

43 filings · 4 bullish · 3 bearish · 1 mixed · 35 neutral
All NVO filing & press-release reports (43)